NCT00151333View on ClinicalTrials.gov

Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
Alzheimer's Disease
Interventions
DRUG

SRA-333

Trial Locations (3)

33154

Miami

33321

Fort Lauderdale

85013

Phoenix

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00151333 - Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD) | Biotech Hunter | Biotech Hunter